ArticleOncology and therapy2024

Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population.

Debora Gagliato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.